{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infratentorial+Glioma", "query": { "condition": "Infratentorial Glioma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 148, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infratentorial+Glioma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T14:56:30.754Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01644773", "title": "Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Intrinsic Pontine Glioma", "High-grade Glioma" ], "interventions": [ { "name": "Crizotinib", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 36, "start_date": "2012-11-27", "completion_date": "2018-09-28", "has_results": false, "last_update_posted_date": "2019-03-22", "last_synced_at": "2026-07-22T14:56:30.754Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644773" }, { "nct_id": "NCT01233479", "title": "Biomarkers in Blood Samples From Young Patients With Newly Diagnosed Brain Tumors Undergoing Standard Radiation Therapy and Chemotherapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "systemic chemotherapy", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "therapeutic surgical procedure", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "Pediatric Brain Tumor Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "4 Years to 21 Years" }, "enrollment_count": 0, "start_date": "2010-05", "completion_date": "2017-08-24", "has_results": false, "last_update_posted_date": "2019-04-01", "last_synced_at": "2026-07-22T14:56:30.754Z", "location_count": 11, "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01233479" }, { "nct_id": "NCT01222754", "title": "Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Intrinsic Pontine Glioma", "Anaplastic Astrocytoma", "High Grade Glioma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "XRT, 54-59.4 Gy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 29, "start_date": "2010-11-23", "completion_date": "2019-04-17", "has_results": false, "last_update_posted_date": "2022-01-03", "last_synced_at": "2026-07-22T14:56:30.754Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01222754" }, { "nct_id": "NCT02502708", "title": "Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme", "Glioma", "Gliosarcoma", "Malignant Brain Tumor", "Ependymoma", "Medulloblastoma", "Diffuse Intrinsic Pontine Glioma", "Primary CNS Tumor" ], "interventions": [ { "name": "Indoximod", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Conformal Radiation", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 81, "start_date": "2015-10", "completion_date": "2020-02-28", "has_results": false, "last_update_posted_date": "2020-06-04", "last_synced_at": "2026-07-22T14:56:30.754Z", "location_count": 5, "location_summary": "Aurora, Colorado • Orlando, Florida • Atlanta, Georgia + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02502708" }, { "nct_id": "NCT00004212", "title": "DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "exatecan mesylate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": null, "start_date": "1999-09", "completion_date": "2004-04", "has_results": false, "last_update_posted_date": "2012-05-16", "last_synced_at": "2026-07-22T14:56:30.754Z", "location_count": 4, "location_summary": "New York, New York • Memphis, Tennessee • Dallas, Texas + 1 more", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004212" }, { "nct_id": "NCT03893487", "title": "Fimepinostat in Treating Brain Tumors in Children and Young Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Diffuse Intrinsic Pontine Glioma", "Recurrent Anaplastic Astrocytoma", "Recurrent Glioblastoma", "Recurrent Malignant Glioma", "Recurrent Medulloblastoma" ], "interventions": [ { "name": "Fimepinostat", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Sabine Mueller, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "3 Years to 39 Years" }, "enrollment_count": 30, "start_date": "2019-08-07", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2025-07-11", "last_synced_at": "2026-07-22T14:56:30.754Z", "location_count": 18, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03893487" }, { "nct_id": "NCT00006246", "title": "Busulfan in Treating Children and Adolescents With Refractory CNS Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Leukemia", "Lymphoma", "Metastatic Cancer", "Retinoblastoma", "Sarcoma" ], "interventions": [ { "name": "busulfan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pediatric Brain Tumor Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 28, "start_date": "2000-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-10-07", "last_synced_at": "2026-07-22T14:56:30.754Z", "location_count": 8, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006246" }, { "nct_id": "NCT00098761", "title": "VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "laromustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pediatric Brain Tumor Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 42, "start_date": "2005-02", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2011-06-30", "last_synced_at": "2026-07-22T14:56:30.754Z", "location_count": 10, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00098761" }, { "nct_id": "NCT00004078", "title": "Irinotecan in Treating Children With Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Childhood Central Nervous System Germ Cell Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood Infratentorial Ependymoma", "Childhood Oligodendroglioma", "Childhood Supratentorial Ependymoma", "Previously Treated Childhood Rhabdomyosarcoma", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Recurrent Childhood Visual Pathway Glioma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Neuroblastoma", "Recurrent Osteosarcoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 181, "start_date": "1999-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-14", "last_synced_at": "2026-07-22T14:56:30.754Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004078" }, { "nct_id": "NCT01922076", "title": "Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Oligoastrocytoma", "Diffuse Intrinsic Pontine Glioma", "Diffuse Midline Glioma, H3 K27M-Mutant", "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "37 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "37 Months to 21 Years" }, "enrollment_count": 46, "start_date": "2013-09-03", "completion_date": "2022-09-30", "has_results": true, "last_update_posted_date": "2024-01-31", "last_synced_at": "2026-07-22T14:56:30.754Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01922076" } ] }